|
| U.S. Brand
Names |
|
| K-Phos® Neutral; Neutra-Phos®;
Uro-KP-Neutral® |

|
|
| Generic
Available |
|
|
Yes |

|
|
| Synonyms |
|
|
Sodium Phosphate and Potassium Phosphate |

|
|
| Pharmacological Index |
|
|
Electrolyte Supplement, Oral |

|
|
| Use |
|
|
Treatment of conditions associated with excessive renal phosphate loss or
inadequate GI absorption of phosphate; to acidify the urine to lower calcium
concentrations; to increase the antibacterial activity of methenamine; reduce
odor and rash caused by ammonia in urine |

|
|
| Pregnancy Risk
Factor |
|
|
C |

|
|
| Contraindications |
|
|
Addison's disease, hyperkalemia, hyperphosphatemia, infected urolithiasis or
struvite stone formation, patients with severely impaired renal
function |

|
|
| Warnings/Precautions |
|
|
Use with caution in patients with renal disease, hyperkalemia, cardiac
disease and metabolic alkalosis |

|
|
| Adverse
Reactions |
|
|
>10%: Gastrointestinal: Diarrhea, nausea, stomach pain, flatulence,
vomiting
1% to 10%:
Cardiovascular: Bradycardia
Endocrine & metabolic: Hyperkalemia
Neuromuscular & skeletal: Weakness
Respiratory: Dyspnea
<1%: Arrhythmia, chest pain, edema, mental confusion, tetany (with large
doses of phosphate), alkalosis, weight gain, throat pain, decreased urine
output, phlebitis, paresthesias, paralysis, pain/weakness of extremities, bone
pain, arthralgia, acute renal failure, shortness of breath, thirst
|

|
|
| Overdosage/Toxicology |
|
|
Symptoms of overdose include muscle weakness, paralysis, peaked T waves,
flattened P waves, prolongation of QRS complex, ventricular arrhythmias, tetany,
calcium phosphate precipitation
Removal of potassium can be accomplished by various means; removal through
the GI tract with Kayexalate® administration; by way of
the kidney through diuresis, mineralocorticoid administration or increased
sodium intake; by hemodialysis or peritoneal dialysis; or by shifting potassium
back into the cells by insulin and glucose infusion; calcium chloride reverses
cardiac effects. |

|
|
| Drug
Interactions |
|
|
Decreased effect/levels with aluminum and magnesium-containing antacids or
sucralfate which can act as phosphate binders
Increased effect/levels with potassium-sparing diuretics or ACE inhibitors;
salicylates |

|
|
| Usual Dosage |
|
|
All dosage forms to be mixed in 6-8 oz of water prior to administration
Adults: 1-2 capsules (250-500 mg phosphorus/8-16 mmol) 4 times/day after
meals and at bedtime |

|
|
| Dietary
Considerations |
|
|
Should be administered after meals |

|
|
| Monitoring
Parameters |
|
|
Serum potassium, sodium, calcium, phosphate, EKG |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
Do not swallow, open capsule and dissolve in 6-8 oz of water; powder packets
are to be mixed in 6-8 oz of water; tablets should be crushed and mixed in 6-8
oz of water |

|
|
| Nursing
Implications |
|
|
Tablets may be crushed and stirred vigorously to speed
dissolution |

|
|
| Dosage Forms |
|
|
See table in Potassium Phosphate
monograph |

|
|
Copyright © 2007 Drugs Area
|